Health Care • Biotechnology: Pharmaceutical Preparations
$149.52 ▲ +3.19
(+2.18%)
MKT CAP: $361.02B • VOL: 12.35M
52W L $82 52W H $157
MRK // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $65.01B | $64.17B | $60.12B |
| YoY Revenue Growth % | +1.3% | +6.7% | — |
| Gross Profit | $48.63B | $48.98B | — |
| Gross Margin % | 74.8% | 76.3% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $21.54B | $20.20B | $430.7M |
| Operating Margin % | 33.1% | 31.5% | 0.7% |
| Net Income (GAAP) | $18.25B | $17.12B | $365.0M |
| EBITDA (Normalized) | $24.83B | $22.90B | $2.59B |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $16.47B | $21.47B | $13.01B |
| Capital Expenditures (CapEx) | $4.11B | $3.37B | $2.71B |
| Free Cash Flow (FCF) | $12.36B | $18.10B | $10.30B |
| FCF Margin % | 19.0% | 28.2% | 17.1% |
| Return on Invested Capital (ROIC %) | 20.1% | 23.6% | 0.3% |
| Cash & Short-Term Equivalents | $14.56B | $13.24B | — |
| Total Debt (Short + Long Term) | $46.75B | $34.46B | $46.46B |
| Total Stockholders' Equity | $52.61B | $46.31B | $95.31B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR MRK.